ArticleCommunications medicine2025
Evolving impact of the COVID-19 pandemic in chronic dialysis recipients in France.
Article in Communications medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThis observational study aimed to assess the impact of the pandemic on the way kidney transplantation, survival, and vaccination evolved in chronic dialysis recipients (CDR) over the course of the COVID-19 pandemic waves and inter-waves.
methodsUsing the French national health claims database, incident persons with end-stage kidney disease in the years 2015 to 2021 treated with dialysis were followed up until 31 December, 2022. Kidney transplantation and survival in the pandemic sub-periods compared to the pre-pandemic period were investigated using longitudinal models with time-dependent covariates. In addition, the impact of cumulative doses of COVID-19 vaccine on hospitalization and survival was studied, comparing CDR and matched controls.
resultsHere, we show that the follow-ups of the 71,583 CDR and the 143,166 controls totalize 639,341 person-years (CDR: 184,909; controls: 454,432). The likelihood of receiving a kidney transplant is lower in all pandemic sub-periods. The 3 waves are associated with a higher risk of death (hazard ratio (HR [95% confidence interval]): 1.19 [1.13-1.27], 1.19 [1.15-1.23], and 1.12 [1.07-1.17], respectively). While vaccine coverage declines with each booster dose, receiving these doses is associated with a lower risk of COVID-19-related hospitalization (0.66 [0.56-0.77], 0.83 [0.72-0.94] for 1
conclusionsThe evolving patterns in mortality and vaccination outcomes are similar in CDR and controls, suggesting that the impact of the pandemic on CDR is not specific to kidney disease per se.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.